Loading clinical trials...
Loading clinical trials...
A Randomized Controlled Study of Dasatinib Combined With Reduced Intensive Consolidation Chemotherapy in Newly Diagosed Philadelphia Chromesome Positive Adult Lymphoblastic Leukemia
Conditions
Interventions
dasatinib plus consolidation chemotherapy with vincristine and prednisone
dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
Locations
1
China
First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Start Date
September 6, 2021
Primary Completion Date
June 30, 2023
Completion Date
June 30, 2023
Last Updated
October 1, 2021
NCT04722848
NCT03541083
NCT07499128
NCT03545659
NCT01429610
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions